

Please note: This document was created automatically and is not a substitute for the manufacturer's original document.

Product Datasheet

Goat IgG anti-Human Kappa light chain-FITC, MinX none DNA-SEC-183017

Article Name	Goat IgG anti-Human Kappa light chain-FITC, MinX none
Biozol Catalog Number	DNA-SEC-183017
Supplier Catalog Number	SEC-183017
Alternative Catalog Number	DNA-SEC-183017
Manufacturer	dianova
Host	Goat
Category	Antikörper
Application	FLISA,FACS,IF
Species Reactivity	Human
Immunogen	Human kappa light chain
Conjugation	FITC
Format	IgG
Target Specificity	Kappa (light chain)
Cross-Adsorption (MinX)	no cross-adsorbtion
Product Description	The anti-Human kappa (kappa chain) Antibody detects the kappa chain subunit. Immunoglobulins are heterotetramers composed of 2 immunoglobulin heavy and 2 immunoglobulin light chains. The immunoglobulin light chain is the small polypeptide subunit of ...
Clonality	Polyclonal

Concentration	1.0 mg/mL
Isotype	Ig
Buffer	0.125 M Sodium Borate, 0.075 M Sodium Chloride, 0.005 M EDTA, pH 8.0
Purity	This product was prepared from monospecific antiserum by immunoaffinity chromatography using Human antigens coupled to agarose beads followed by solid phase adsorption(s) to remove any unwanted reactivities. Assay by immunoelectrophoresis resulted in a single precipitin arc against anti-Fluorescein and anti-Goat Serum. Specificity was confirmed by ELISA minimal cross-reactivity against other human heavy or light chain isotypes.
Form	Lyophilized
Formula	125 mM Sodium Borate, 75 mM NaCl, 5 mM EDTA, pH 8.0, lyophilisate, 0.01% NaN ₃
Target	Human
Antibody Type	Secondary Antibody
Application Dilute	FLISA Dilution: 1:10,000 - 1:50,000, Flow Cytometry Dilution: 1:500 - 1:2,500, Fluorochrome Protein Value: 8.0, IF Microscopy Dilution: 1:1,000 - 1:5,000
Application Notes	This product is designed for immunofluorescence microscopy, fluorescence based plate assays (FLISA) and fluorescent western blotting. This product is also suitable for multiplex analysis, including multicolor imaging, utilizing various commercial platforms.